Lite Strategy, Inc. Operating Lease, Payments
Lite Strategy, Inc. (LITS) reported Operating Lease, Payments of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2025-11-14
- Lite Strategy, Inc. operating lease, payments for the quarter ending 2025-09-30 was $0.00.
- Lite Strategy, Inc. operating lease, payments for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Lite Strategy, Inc. operating lease, payments for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Lite Strategy, Inc. operating lease, payments for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Lite Strategy, Inc. operating lease, payments for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Lite Strategy, Inc. operating lease, payments for fiscal 2024 was $13.61M, a 500.44% increase from fiscal 2023.
- Lite Strategy, Inc. operating lease, payments for fiscal 2023 was $2.27M, a 49.24% increase from fiscal 2022.
- Lite Strategy, Inc. operating lease, payments for fiscal 2022 was $1.52M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 derived: sum of 3 quarters · filed 2025-11-14 | $0.00 derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-26 | $0.00 derived: sum of 2 quarters · filed 2025-09-26 | $0.00 derived: sum of 3 quarters · filed 2025-09-26 | $0.00 10-K · filed 2025-09-26 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2025-05-13 | $0.00 10-Q · filed 2025-05-13 | $11.86M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-12-31 | $0.00 10-Q · filed 2025-02-12 | $0.00 10-Q · filed 2025-02-12 | $11.86M derived: sum of 3 quarters · filed 2025-11-14 | $12.45M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $11.86M derived: sum of 2 quarters · filed 2025-11-14 | $12.45M derived: sum of 3 quarters · filed 2025-11-14 | $13.03M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $11.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-26 | $12.45M derived: sum of 2 quarters · filed 2025-09-26 | $13.03M derived: sum of 3 quarters · filed 2025-09-26 | $13.61M 10-K · filed 2025-09-26 |
| 2024-03-31 | $584.00K 10-Q · filed 2025-05-13 | $1.17M derived: sum of 2 quarters · filed 2025-05-13 | $1.75M 10-Q · filed 2025-05-13 | $2.32M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $583.00K 10-Q · filed 2025-02-12 | $1.17M 10-Q · filed 2025-02-12 | $1.73M derived: sum of 3 quarters · filed 2025-02-12 | $2.30M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-09-30 | $584.00K 10-Q · filed 2024-11-12 | $1.15M derived: sum of 2 quarters · filed 2024-11-12 | $1.72M derived: sum of 3 quarters · filed 2024-11-12 | $2.29M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $567.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-19 | $1.13M derived: sum of 2 quarters · filed 2024-09-19 | $1.70M derived: sum of 3 quarters · filed 2024-09-19 | $2.27M 10-K · filed 2024-09-19 |
| 2023-03-31 | $567.00K 10-Q · filed 2024-05-09 | $1.13M derived: sum of 2 quarters · filed 2024-05-09 | $1.70M 10-Q · filed 2024-05-09 | $2.08M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $567.00K 10-Q · filed 2024-02-13 | $1.13M 10-Q · filed 2024-02-13 | $1.51M derived: sum of 3 quarters · filed 2024-02-13 | $1.89M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $567.00K 10-Q · filed 2023-11-09 | $947.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.33M derived: sum of 3 quarters · filed 2023-11-09 | $1.71M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $380.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-26 | $760.00K derived: sum of 2 quarters · filed 2023-09-26 | $1.14M derived: sum of 3 quarters · filed 2023-09-26 | $1.52M 10-K · filed 2023-09-26 |
| 2022-03-31 | $380.00K 10-Q · filed 2023-05-11 | $760.00K derived: sum of 2 quarters · filed 2023-05-11 | $1.14M 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $380.00K 10-Q · filed 2023-02-09 | $760.00K 10-Q · filed 2023-02-09 | ||
| 2021-03-31 | $369.00K 10-Q · filed 2021-05-06 | $492.00K derived: sum of 2 quarters · filed 2021-05-06 | $615.00K 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $123.00K 10-Q · filed 2021-02-04 | $246.00K 10-Q · filed 2021-02-04 | ||
| 2020-03-31 | $201.00K 10-Q · filed 2021-05-06 | $402.00K derived: sum of 2 quarters · filed 2021-05-06 | $603.00K 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $201.00K 10-Q · filed 2021-02-04 | $402.00K 10-Q · filed 2021-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |